Abstract
Background The Banff classification standardizes the diagnoses of kidney transplant rejection based on histological criteria. Clinical decisions are generally made after integration of the Banff diagnoses in the clinical context. However, interpretation of the biopsy cases is still heterogeneous among pathologists or clinicians. Machine Learning (ML) algorithms may be trained from expertly assessed cases to provide clinical decision support.
Methods The ML technique of Extreme Gradient Boosting learned from two large training datasets from the European programs BIOMARGIN and ROCKET (n= 631 and 304), in which biopsies were read centrally and consensually interpreted by a group of experts and used as a reference for untargeted biomarker screenings. The model was then externally validated in three independent datasets (n= 3744, 589 and 360).
Results In the three validation datasets, the algorithm yielded a ROC curve AUC of mean (95% CI) 0.97 (0.92-1.00), 0.97 (0.96-0.97) and 0.95 (0.93-0.97) for antibody-mediated rejection (ABMR); 0.94 (0.91-0.96), 0.94 (0.92-0.95) and 0.91 (0.88-0.95) for T cell-mediated rejection; >0.96 (0.90-1.00) in all three for interstitial fibrosis - tubular atrophy (IFTA). Finally, using the largest validation cohort, we developed an additional algorithm to discriminate active and chronic active ABMR with an accuracy of 0.95.
Conclusion We built an Artificial Intelligence algorithm able to interpret histological lesions together with a few routine clinical data with very high sensitivity and specificity. This algorithm should be useful in routine or clinical trials to help pathologists and clinicians and increase biopsy interpretation homogeneity.
Competing Interest Statement
M. Naesens reports being a scientific advisor to or Editorial Board member of several journals and Advisor for the European Medicines Agency. All remaining authors have nothing to disclose.
Clinical Trial
NCT02832661
Funding Statement
This project was supported by ERACoSysMed-2, the ERA-Net for Systems Medicine in clinical research and medical practice (project ROCKET, JTC2 29).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the ethics committee of Ile-de-France XI, the comite de protection des personnes du Sud-Ouest et Outre-Mer IV, and the Ethical Committe of the University Hospitals Leuven.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
